Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Current Deferred Revenue: 2023-2024

Historic Current Deferred Revenue for BioLineRx (BLRX) over the last 1 years, with Sep 2024 value amounting to $2.3 million.

  • BioLineRx's Current Deferred Revenue was N/A to $2.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $13.0 million for FY2023, which is N/A change from last year.
  • Per BioLineRx's latest filing, its Current Deferred Revenue stood at $2.3 million for Q3 2024, which was up 130.15% from -$7.5 million recorded in Q2 2024.
  • BioLineRx's 5-year Current Deferred Revenue high stood at $13.0 million for Q4 2023, and its period low was -$7.5 million during Q2 2024.
  • For the 2-year period, BioLineRx's Current Deferred Revenue averaged around $4.2 million, with its median value being $5.6 million (2024).